Bliss GVS Pharma Board Meeting Scheduled on May 12, 2026 to Approve Q4 FY26 Results and Final Dividend

Bliss GVS Pharma has informed the stock exchanges of a scheduled Board of Directors meeting on Tuesday, May 12, 2026, at its registered office. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting has been convened to consider and approve key financial matters pertaining to the quarter and full financial year ended March 31, 2026.

Agenda for the Board Meeting

The board meeting has been called to deliberate on the following key items, as outlined in the regulatory filing:

Agenda Item:	Details
Financial Results:	Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
Additional Statements:	Statement of Assets and Liabilities, Cash Flow Statement, and Audit Report (with modified opinion, if any)
Financial Statements:	Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026
Dividend Consideration:	Recommendation of Final Dividend, if any, for the financial year ended March 31, 2026

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of Bliss GVS Pharma has been closed for all Designated Persons and their immediate relatives. The closure took effect from April 01, 2026, and will remain in force until 48 hours after the announcement or declaration of the audited financial results for the quarter and year ended March 31, 2026, or until the information becomes generally available.

The intimation has been signed by Aditi Bhatt, Company Secretary, and has also been uploaded to the Company's official website at https://www.blissgvs.com/corporate-announcement .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.51%	+1.74%	+14.63%	+78.97%	+139.54%	+162.30%

Bliss GVS Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of two independent directors through a remote e-voting process. The pharmaceutical company published the notice in leading newspapers on April 10, 2026, in compliance with SEBI listing regulations.

Proposed Director Appointments

The company is seeking approval for two special resolutions related to director appointments:

Sr. No.	Director Details	Position	Term	Resolution Type
1.	Mr. Vijayanarayanan Mahadevan (DIN: 06639177)	Non-Executive Independent Director	Five Years	Special Resolution
2.	Mr. Deepak Rameshchandra Shah (DIN: 06954206)	Non-Executive Independent Director	Five Years	Special Resolution

E-Voting Process and Timeline

The postal ballot will be conducted exclusively through remote e-voting, with no physical ballot forms being distributed to shareholders. The company has engaged Central Depository Securities Limited (CDSL) to facilitate the electronic voting process.

Key Dates and Timeline

Parameter:	Details
Cut-off Date:	Tuesday, April 07, 2026
Notice Dispatch:	Thursday, April 09, 2026
Voting Commencement:	Friday, April 10, 2026, at 9:00 a.m. (IST)
Voting Conclusion:	Saturday, May 09, 2026, at 5:00 p.m. (IST)
Result Declaration:	On or before May 12, 2026

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as of the cut-off date are eligible to participate in the voting process. Voting rights will be calculated based on the paid-up value of equity shares registered in shareholders' names as of April 7, 2026.

Regulatory Compliance and Documentation

The postal ballot notice has been prepared in accordance with Section 110 read with Section 108 of the Companies Act, 2013, and Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014. The process also complies with MCA General Circular No. 14/2020 dated April 8, 2020, and subsequent circulars, including General Circular No. 03/2025 dated September 22, 2025.

The notice is available on multiple platforms for shareholder access:

• Company website: www.blissgvs.com • CDSL website: https://www.cdslindia.com/ • BSE website: https://www.bseindia.com/ • NSE website: https://www.nseindia.com/

Scrutinizer Appointment

The Board of Directors has appointed Mr. Vijay Yadav (Membership No. FCS 11990 and COP No. 16806), Partner of AVS & Associates, Practising Company Secretaries, as the Scrutinizer for conducting the postal ballot process. The scrutinizer will ensure fair and transparent conduct of the e-voting process, with their decision on ballot validity being final.

Shareholder Support and Assistance

Shareholders requiring assistance with the e-voting process can access support through multiple channels. The company has provided access to Frequently Asked Questions (FAQs) and an e-voting manual at www.evotingindia.com . Additionally, shareholders can contact the toll-free number 1800 21 09911 or reach out to Mr. Rakesh Dalvi, Senior Manager at CDSL, via helpdesk.evoting@cdslindia.com for technical support.

The results of the postal ballot will be communicated to stock exchanges where the company's equity shares are listed and will be displayed on both CDSL's website and the company's official website following the declaration.